The Board of Welcure Drugs & Pharmaceuticals considered the letter of intent signed by Singapore -based Telexcell Trade PTE to buy 25 per cent stake at ₹20 per share in the company.

The Board believes the fresh strategic investment will boost global investor confidence while preserving independence, creating a mutually beneficial result for the company, its shareholders, and stakeholders.

Both parties are expected to complete the due diligence and documentation process in 90 days. This strategic investment is aimed at enhancing Welcure’s global footprint, leveraging growing opportunities in emerging markets.

“Telexcell initially expressed interest not only in acquiring a significant shareholding but also sought a level of influence in the management and decision-making of the compan

See Full Page